Results 11 to 20 of about 70,416 (256)

Sorafenib-induced acute pancreatitis

Journal of Medical Sciences, 2014
Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade
Han-En Wang, Chun-Ting Chen, Hsin-Hung Huang   +2 more
doaj   +2 more sources

In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

International Journal of Nanomedicine, 2016
Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharmaceutics, College of Pharmacy, Shandong University, 2Shandong Provincial Key Laboratory of Neuroprotective Drug, Jinan, Shandong Province, People’s ...
Yang S, Zhang B, Gong X, Wang T, Liu Y, Zhang N   +5 more
doaj   +1 more source

Magnetoreceptor Promotes Hepatocellular Carcinoma Development and Blunts Sorafenib-Induced Ferroptosis by Regulating Iron Homeostasis. [PDF]

Adv Sci (Weinh)
Magnetoreceptor (MagR) regulates iron homeostasis and mitochondrial function in hepatocellular carcinoma (HCC) cells. Specifically, MagR deficiency suppresses tumor cell proliferation, migration, and invasion and enhances sorafenib‐induced ferroptosis through iron accumulation.
Wang T, Song C, He X, Wang M, Liu W, Wang X, Zhang Y, Zhang J, Zhang L, Li D, Zhang Y, Wu Z, Lyu Y, Wu R.   +13 more
europepmc   +2 more sources

Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway

Molecular and Cellular Probes, 2023
Backgrounds: Sorafenib-resistance leads to poor prognosis and high mortality in advanced hepatocellular carcinoma (HCC), and this study aims to investigate the functional role of a circular RNA ITCH (circITCH) in regulating the sorafenib-resistance of ...
Xiaodong Li, Xuedong Yin, Heyi Bao, Chang Liu   +3 more
doaj   +1 more source

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Scientific Reports, 2021
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy.
Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu   +7 more
doaj   +1 more source

Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.

, 2021
Background: We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab.Case report: Case 1: A 50-year-old man with RCC received nivolumab as ...
FUJIMOTO, Noriki, 8611, 50378460, KAGEYAMA, Susumu, KAWAUCHI, Akihiro, 8612, 6456, 2909, KATO, Takeshi, 2792, 2890, 小出, 博義, TERADA, Tomohiro, 0000-0001-7150-647X, 674, 675, 吉田, 哲也, 10324641, 60510310, 河内, 明宏, 寺田, 智祐, KOIDE, Hiroyoshi, 6322, 影山, 進, 50378452, 60865707, 90240952, 野田, 哲史, 藤本, 徳毅, 0000-0003-4051-0649, 0000-0001-9969-7159, NODA, Satoshi, 0000-0001-6344-4440, 寺村, 和也, 加藤, 威, TERAMURA, Kazuya, YOSHIDA, Tetsuya   +36 more
core   +1 more source

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2

Biology, 2023
Sorafenib, a kinase inhibitor, has shown promising therapeutic efficacy in a subset of patients with acute myeloid leukemia (AML). However, despite its clinical effectiveness, sorafenib resistance is frequently observed in clinical settings, and the ...
Xi Xu, Weiwei Ma, Guo Qiu, Li Xuan, Chong He, Tian Zhang, Jian Wang, Qifa Liu   +7 more
doaj   +1 more source

Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells

Non-Coding RNA, 2022
The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern.
Qingchun Lu, Mingyang Xin, Qian Guo, Brad S. Rothberg, Ana M. Gamero, Ling Yang   +5 more
doaj   +1 more source

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel [PDF]

, 2013
Introduction: Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases.
John M Kirkwood, Keith T Flaherty, Fengmin Zhao (139710), Kluger Harriet M., Wilson, M, Harriet M Kluger, Jilaveanu Lucia B., Rimm, DL, Lee, Sandra J., Kurt D'Andrea (442217), Rimm David L., Harriet M. Kluger (184091), Kluger, HM, D'Andrea, Kurt, Zhao, F, Kurt D'Andrea, Melissa Wilson (442218), Keith T. Flaherty (226339), Nathanson, KL, Kirkwood, John M., Sandra J. Lee (213144), Lee Sandra J., Fengmin Zhao, D'Andrea, K, Zhao, Fengmin, David L. Rimm (323315), Kirkwood, JM, Flaherty Keith T., Kirkwood John M., Sandra J Lee, Wilson Melissa, Katherine L Nathanson, Flaherty, Keith T., Jilaveanu, LB, John M. Kirkwood (141762), David L Rimm, Rimm, David L., Nathanson Katherine L., Zito, Christopher R., D'Andrea Kurt, Zito, CR, Lucia B Jilaveanu, Zhao Fengmin, Wilson, Melissa, Jilaveanu, Lucia B., Flaherty, KT, Lee, SJ, Katherine L. Nathanson (154077), Melissa Wilson, Smalley, Keiran, Lucia B. Jilaveanu (184077), Kluger, Harriet M., Christopher R. Zito (184074), Zito Christopher R., Christopher R Zito, Nathanson, Katherine L.   +55 more
core   +2 more sources

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular CarcinomaSummary

Cellular and Molecular Gastroenterology and Hepatology, 2020
Background & Aims: Sorafenib is a multireceptor tyrosine kinase inhibitor that can prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Although most HCC patients who receive sorafenib ultimately show disease progression,
Tomomi Hashiba, Taro Yamashita, Hikari Okada, Kouki Nio, Takehiro Hayashi, Yoshiro Asahina, Tomoyuki Hayashi, Takeshi Terashima, Noriho Iida, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Takamura, Tetsuo Ohta, Masao Honda, Shuichi Kaneko   +19 more
doaj   +1 more source